Specificity and sensitivity of the Abeta oligomer ELISA

Journal of Neuroscience Methods

Volumn 195, Issue 2, 2011, Pages 249-254

  Klaver, Andrea C ^a   Patrias, Lynnae M ^a   Finke, John M ^b   Loeffler, David A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b OAKLAND UNIVERSITY   (United States)

Author keywords

Abeta; Alzheimer's disease; Amyloid beta; ELISA; Oligomers; Western blot

Indexed keywords

AMYLOID BETA PROTEIN; EPITOPE; MONOCLONAL ANTIBODY; MONOMER; OLIGOMER;

ARTICLE; BIOTINYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL; MOLECULAR WEIGHT; OPTICAL DENSITY; PRIORITY JOURNAL; PROTEIN BINDING; SENSITIVITY AND SPECIFICITY; SPECIES; STORAGE TEMPERATURE; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; ANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MOLECULAR WEIGHT; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; SENSITIVITY AND SPECIFICITY;

EID: 78751702597     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2010.12.001     Document Type: Article

References (33)

1. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42:631-639.
2. Bierer L.M., Hof P.R., Purohit D.P., Carlin L., Schmeidler J., Davis K.L., et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol 1995, 52:81-88.
3. Bitan G., Lomakin A., Teplow D.B. Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J Biol Chem 2001, 276:35176-35184.
4. Dulin F., Léveillé F., Ortega J.B., Mornon J.P., Buisson A., Callebaut I., et al. P3 peptide, a truncated form of Abeta devoid of synaptotoxic effect, does not assemble into soluble oligomers. FEBS Lett 2008, 582:1865-1870.
5. El-Agnaf O.M., Mahil D.S., Patel B.P., Austen B.M. Oligomerization and toxicity of beta-amyloid-42 implicated in Alzheimer's disease. Biochem Biophys Res Commun 2000, 273:1003-1007.
6. Englund H., Sehlin D., Johansson A.S., Nilsson L.N., Gellerfors P., Paulie S., et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem 2007, 103:334-345.
7. Fein J.A., Sokolow S., Miller C.A., Vinters H.V., Yang F., Cole G.M., et al. Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes. Am J Pathol 2008, 172:1683-1692.
8. Funke S.A., Birkmann E., Willbold D. Detection of amyloid-beta aggregates in body fluids: a suitable method for early diagnosis of Alzheimer's disease?. Curr Alzheimer Res 2009, 6:285-289.
9. Georganopoulou D.G., Chang L., Nam J.M., Thaxton C.S., Mufson E.J., Klein W.L., et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 2005, 102:2273-2276.
10. Giannakopoulos P., Herrmann F.R., Bussière T., Bouras C., Kövari E., Perl D.P., et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003, 60:1495-1500.
11. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991, 12:383-388.
12. Howlett D., Cutler P., Heales S., Camilleri P. Hemin and related porphyrins inhibit beta-amyloid aggregation. FEBS Lett 1997, 417:249-251.
13. Huang T.H., Yang D.S., Plaskos N.P., Go S., Yip C.M., Fraser P.E., et al. Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide. J Mol Biol 2000, 297:73-87.
14. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
15. Klaver A.C., Finke J.M., Digambaranath J., Balasubramaniam M., Loeffler D.A. Antibody concentrations to Aβ1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. Int Immunopharm 2010, 10:115-119.
16. Lee E.B., Leng L.Z., Zhang B., Kwong L., Trojanowski J.Q., Abel T., et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 2006, 281:4292-4299.
17. LeVine H. Quantification of beta-sheet amyloid fibril structures with Thioflavin T. Methods Enzymol 1999, 309:274-284.
18. LeVine H. Alzheimer's beta-peptide oligomer formation at physiologic concentrations. Anal Biochem 2004, 335:81-90.
19. Lublin A.L., Gandy S. Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's disease. Mt Sinai J Med 2010, 77:43-49.
20. McLaurin J., Cecal R., Kierstead M.E., Tian X., Phinney A.L., Manea M., et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002, 8:1263-1269.
21. Oddo S., Caccamo A., Tran L., Lambert M.P., Glabe C.G., Klein W.L., et al. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem 2006, 281:1599-1604.
22. Portelius E., Andreasson U., Ringman J.M., Buerger K., Daborg J., Buchhave P., et al. Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Mol Neurodegener 2010, 5:2.
23. Ramakrishnan M., Kandimalla K.K., Wengenack T.M., Howell K.G., Poduslo J.F. Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid beta peptide-capturing and plaque-binding monoclonal antibodies. Biochemistry 2009, 48:10405-10415.
24. Sastre M., Steiner H., Fuchs K., Capell A., Multhaup G., Condron M.M., et al. Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep 2001, 2:835-841.
25. Sehlin D., Söllvander S., Paulie S., Brundin R., Ingelsson M., Lannfelt L., et al. Interference from heterophilic antibodies in amyloid-beta oligomer ELISAs. J Alzheimer Dis 2010, August. [Epub ahead of print].
26. Sian A.K., Frears E.R., El-Agnaf O.M., Patel B.P., Manca M.F., Siligardi G., et al. Oligomerization of beta-amyloid of the Alzheimer's and the Dutch-cerebral-haemorrhage types. Biochem J 2000, 349:299-308.
27. Teplow D.B. Preparation of amyloid beta-protein for structural and functional studies. Methods Enzymol 2006, 413:20-33.
28. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30:572-580.
29. Tomic J.L., Pensalfini A., Head E., Glabe C.G. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 2009, 35:352-358.
30. Van Dooren T., Muyllaert D., Borghgraef P., Cresens A., Devijver H., Van der Auwera I., et al. Neuronal or glial expression of human apolipoprotein e4 affects parenchymal and vascular amyloid pathology differentially in different brain regions of double- and triple-transgenic mice. Am J Pathol 2006, 168:245-260.
31. van Helmond Z., Heesom K., Love S. Characterisation of two antibodies to oligomeric Abeta and their use in ELISAs on human brain tissue homogenates. J Neurosci Methods 2009, 176:206-212.
32. Wirths O., Multhaup G., Bayer T.A. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide-the first step of a fatal cascade. J Neurochem 2004, 91:513-520.
33. Xia W., Yang T., Shankar G., Smith I.M., Shen Y., Walsh D.M., et al. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 2009, 66:190-199.